Arrowhead Pharmaceuticals vs Ionis Pharmaceuticals
ARWR and IONS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARWR and IONS compare
Arrowhead Pharmaceuticals is the larger company, worth 1.2 times as much as Ionis Pharmaceuticals ($8.5B against $7.2B).
Arrowhead Pharmaceuticals grew revenue faster over the last twelve months (16.8% versus −7.4% for Ionis Pharmaceuticals).
Arrowhead Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −47.8% compared with −64.7% at Ionis Pharmaceuticals.
Arrowhead Pharmaceuticals scores higher on the StockData Score (5 against 3 for Ionis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARWR | IONS |
|---|---|---|
| Size and price | ||
| Market cap | $8.5B | $7.2B |
| Share price | $59.90 | $43.52 |
| Change, 1 year | 48.7% | −39.5% |
| Change, 5 years | −25.8% | 29.2% |
| Beta (5Y) | 1.73 | 0.71 |
| Employees | 711 | 1,402 |
| StockData Score | ||
| Total score | 5 (better) | 3 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 2 (better) | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 12.6× | 8.3× (better) |
| P/B | 18.2× | 16.4× (better) |
| FCF yield | −0.89% (better) | −7.8% |
| Fair value | $32.22 | $28.12 |
| Margin of safety | −85.9% | −54.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 16.8% (better) | −7.4% |
| Revenue growth, 5Y average | 56.6% (better) | 5.3% |
| Profitability | ||
| Gross margin | – | 98.2% |
| Operating margin | −33.8% (better) | −68.0% |
| Net margin | −47.8% (better) | −64.7% |
| FCF margin | −11.2% (better) | −64.2% |
| Return on equity | −64.8% (better) | −105% |
| Financial health | ||
| Interest coverage | −2.4× (better) | −31.6× |
| Current ratio | 5.90 | 7.89 (better) |
| Altman Z-score | 2.56 (better) | 0.88 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 84.6% | 108% |
| Held by insiders | 4.0% | 0.80% |
| Insider net buying, 12 months | −$37.3M (better) | −$123M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 7.9% | 13.7% |
Go deeper
- ARWR stock overview
- ARWR income statement
- ARWR valuation and score
- IONS stock overview
- IONS income statement
- IONS valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.